Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital-Reference-Cited by-同舟云学术

Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital

Published:2019-06-28 Issue:7 Volume:31 Page:698-701
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Elberdín L.¹,Fernández-Torres Rm²,Paradela S.²,Blanco E.²,Outeda M.¹,Martín I.¹,Fonseca E.²

Affiliation:

1. Department of Pharmacy, Complexo Hospitalario Universitario de A Coruña (CHUAC), Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidade da Coruña (UDC), A Coruña, Spain;

2. Department of Dermatology, Complexo Hospitalario Universitario de A Coruña (CHUAC), Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidade da Coruña (UDC), A Coruña, Spain

Funder

Novartis, Pfizer, Shire, Abbvie, Celgene, Janssen-Cilag, Leo, MSD, Almirall, Sanofi, and Roche

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2019.1605140

Reference11 articles.

1. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

2. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

3. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients